Journals / Nöropsikiyatri Arşivi / 2014 / Cilt: 51 - Sayı: 4

Bir nöroloji kliniğindeki servikal distonili hastaların klinik özellikleri ve uzun süreli botulinum toksin tip a tedavisine yanıtı

Clinical characteristics and response to long-term botulinum toxin type a therapy in patients with cervical dystonia at a neurology clinic

Pages
383–388
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our results showed a statistically significant increase in the mean dose of BoNT-A, the response rating, the number of muscles applied, the duration of improvement, and the injection interval over time.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: To determine the demographic and clinical characteristics and response to botulinum toxin type A (BoNT-A) therapy in patients with cervical dystonia (CD).
📊
Key Findings & Data:Method: A retrospective analysis of the detailed medical records of the patients with CD, followed up at our Botulinum Toxin Outpatient Clinic from 1998 to 2012, was performed.
💡
Conclusion & Impact:Our results showed a statistically significant increase in the mean dose of BoNT-A, the response rating, the number of muscles applied, the duration of improvement, and the injection interval over time.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Introduction: To determine the demographic and clinical characteristics and response to botulinum toxin type A (BoNT-A) therapy in patients with cervical dystonia (CD). Method: A retrospective analysis of the detailed medical records of the patients with CD, followed up at our Botulinum Toxin Outpatient Clinic from 1998 to 2012, was performed. The treatment data were compared between the patients with primary CD and those with secondary CD; between patients receiving BoNT-A treatment for more than 5 years and less than five years, and between first applications and last applications. Results: Fifty-seven patients (56.15% women) with CD were included in this study. The mean age was 41.01±13.42 years, the mean age at symptom onset was 32.93±15.45 years, and the mean dystonia duration was 8.10±8.5 years. The interval between onset of symptom and first BoNT-A treatment was 5.94±9.06 years, the duration of BoNT-A treatment was 36.13±29.17 months, and the number of applications was 8.48±6.23 in 45 patients with CD who were under treatment with BoNT-A for more than 1 year and had received at least three injections before. There was no difference between the patients with primary and secondary CD in terms of treatment results. The injection interval of the patients receiving BoNT-A treatment for more than 5 years and less than 5 years was 18.37±5.10 and 14.43±2.36 weeks, respectively (p=0.001). There were no differences in the other treatment values. The mean doses were 559.00±147.60 vs. 681.66±188.09 units (p=0.0001), the durations of improvement were 11.82±2.71 vs. 13.00±4.00 weeks (p=0.014), the response scores were 2.71±0.3 vs. 3.02±0.5 (p=0.002), the response ratings were 64.66%±16.18 vs. 71.22%±17.29 (p=0.001), and the numbers of muscles applied were 3.15±1.16 vs. 3.51±0.99 (p=0.012) in the first and last applications, respectively. Conclusion: There were no differences between the response of the patients with primary and secondary CD. Our results showed a statistically significant increase in the mean dose of BoNT-A, the response rating, the number of muscles applied, the duration of improvement, and the injection interval over time.

Özet

Giriş: Servikal distoni (SD)’li hastaların klinik ve demografik özellikleriyle botulinum toksin tip A (BoNT-A) tedavisine yanıtlarını değerlendirmek. Yöntem: Hastanemiz Nöroloji Kliniği Botulinum Toksin Polikliniği’nde 1998-2012 yılları arasında takip edilen SD’li hastaların ayrıntılı tıbbi kayıtları retrospektif olarak değerlendirildi. Birincil ve ikincil SD’lilerin, beş yıldan uzun ve kısa süreli BoNT-A tedavisi alanların verileri, ayrıca ilk ve son tedavi verileri karşılaştırıldı. Bulgular: Çalışmaya alınan 57 (%56,15’i kadın) SD’li hastanın yaş ortalaması 41,01±13,42 yıl, semptomların başlama yaşı ortalama 32,93±15,45 yıl, ortalama distoni süresi 8,10±8,5 yıldı. Bir yıldan uzun takipli ve en az üç uygulama yapılmış 45 hastanın tedavi verileri ortalamaları; tedavi gecikmesi 5,94±9,06 yıl, tedavi süresi 36,13±29,17 ay, tedavi sayısı 8,48±6,23 idi. Birincil ve ikincil SD’li hastaların tedavi yanıtları arasında fark yoktu. Beş yıldan uzun ve kısa süreli BoNT-A tedavisi alanların ortalama BoNT-A uygulama aralığı 18,37±5,10 ve 14,43±2,36 hafta (p=0,001) idi, diğer tedavi verileri arasında anlamlı fark yoktu. Sırayla ilk ve son uygulamadaki ortalama tedavi verileri; BoNT-A dozu 559,00±147,60 ve 681,66±188,09 U (p=0,0001), tedavi etkinlik süresi 11,82±2,71 ve 13,00±4,00 hafta (p=0,014), tedaviye yanıt derecesi 2,71±0,3 ve 3,02±0,5 (p=0,002), düzelme oranı %64,66±16,18 ve %71,22±17,29 (p=0,001) ve uygulama yapılan kas sayısı 3,15±1,16 ve 3,51±0,99 (p=0,012) bulundu. Sonuç: Birincil ve ikincil SD’lilerin tedaviye yanıtları arasında fark yoktu. Sonuçlarımız, zamanla ortalama BoNT-A dozu, düzelme oranı, enjeksiyon yapılan kas sayısı, etkinlik süresi ve uygulama aralığında istatistiksel olarak anlamlı artış olduğunu gösterdi.

🔖

Cite This Article

ŞEN, A., SOYSAL, A., ARPACI, B. (2014). Bir nöroloji kliniğindeki servikal distonili hastaların klinik özellikleri ve uzun süreli botulinum toksin tip a tedavisine yanıtı. Nöropsikiyatri Arşivi, Cilt: 51 - Sayı: 4, 383–388. https://ajindex.com/articles/292450

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991; 41:1088-1091. [CrossRef] 2.Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical cha- racteristics. Mov Disord 1991; 6:119-126. [CrossRef] 3.Fahn S, Marsden CD, Calne DB. Classification and investigation of dystonia. Marsden CD, Fahn S, editörler. Movement Disorders içinde. 2. Baskı. London: Butteworths; 1987; s. 332-358. 4. Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord 2007; 13:411-416. [CrossRef] 5. Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton LJ 3rd. Epi- demiology of focal and generalized dystonia in Rochester, Minne- sota. Mov Disord 1988; 3:188-194.[CrossRef] 6. Leube B, Hendgen T, Kessler KR, Knapp M, Benecke R, Auburger G. Evi- dencefor DYT7 being a common cause of cervical dystonia (torticollis) in Central Europe. Am J Med Genet 1997; 74:529-532. [CrossRef] 7. Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallet M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Aca- demy of Neurology. Neurology 2008; 70:1699-1706. [CrossRef] 8. Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G, Gasser T, Krauss JK, Nardocci N, Newton A, Valls-Sole J. EFNS guideli- nes on diagnosis and treatment of primary dystonias. Eur J Neurol 2011; 18:5-18. [CrossRef] 9. Consky ES, Lang AE. Clinical assessments of patients with cervi- cal dystonia. Jancovic J, Hallett M, editörler. Therapy with botuli- num toxin içinde. New York: Marcel Dekker; 1994; s. 211-237. 10. Rondot P, Marchand MP, Dellatolas G. Spasmodic torticollis-review of 220 patients. Can J Neurol Sci 1991; 18:143-151. 11. Freidman A, Fahn S. Spontaneous remissions in spasmodic torti- collis. Neurology 1986; 36:398-400. [CrossRef] 12. Jahanshani M, Marion MH, Marsden CD. Natural history of adult-onset idiopathic spasmodic torticollis. Arch Neurol 1990; 47:548-552. [CrossRef] 13. Godeiro-Junior C, Felicio AC, Aguiar PC, Borges V, Silva SM, Ferraz HB. Neuroleptic-induced tardive cervical dystonia: clinical series of 20 patients. Can J Neurol Sci 2009; 36:222-226. [CrossRef] 14. Lowenstein DH, Aminoff MJ. The clinical course of spasmodic tor- ti